In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker

Maria Mody, Yoann Petibon, Paul Kyu Han, Darshini Kuruppu, Chao Ma, Daniel Yokell, Ramesh Neelamegam, Marc D. Normandin, Georges El Fakhri, Anna‐Liisa BrownellScientific 2021 · DOI

TL;DR

This study uses PET-MR imaging with a novel radiotracer to show reduced availability of mGlu5 receptors in the brains of males with Fragile X Syndrome (FXS). These findings suggest that mGlu5 receptor availability could serve as a valuable biomarker for FXS, potentially aiding in the development of more effective targeted therapies.

What Problem Does This Paper Address?

Fragile X Syndrome (FXS) is a leading genetic cause of inherited intellectual disability and a common contributor to autism spectrum disorder. A key feature of FXS is the loss of the Fragile X Mental Retardation Protein (FMRP), which is thought to lead to an overactive glutamate signaling pathway, particularly involving metabotropic glutamate subtype 5 receptors (mGluR5). While preclinical studies in mouse models have shown promise for targeting mGluR5 with antagonists to alleviate FXS symptoms, clinical trials in humans have yielded limited success. This lack of success may be due to a need for better outcome measures and biomarkers to assess drug efficacy and target engagement. The paper addresses this by investigating whether mGluR5 receptor availability can be reliably measured in vivo in humans with FXS and if it differs from healthy controls, thereby establishing a potential biomarker for future drug development.

Methods

The researchers employed simultaneous Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) on a hybrid PET-MR scanner. They used a novel radiotracer, 3-[<sup>18</sup>F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([<sup>18</sup>F]FPEB), which specifically binds to mGlu5 receptors. This tracer was administered intravenously to participants, and PET scans were acquired over 90 minutes to capture the tracer's uptake and distribution in the brain.

The core analytical technique was multi-linear reference tissue analysis of the dynamic PET data to estimate the non-displaceable binding potential (BP<sub>ND</sub>) of [<sup>18</sup>F]FPEB. BP<sub>ND</sub> is a quantitative measure of the availability of mGlu5 receptors. Regions of interest (ROIs) were defined based on an MNI template, and TACs (time-activity curves) were extracted for 18 brain regions implicated in FXS symptomatology. Statistical comparisons of BP<sub>ND</sub> values between the FXS group and age- and gender-matched healthy controls were performed using unpaired t-tests, with corrections for multiple comparisons using the Benjamini, Krieger, and Yekutieli false discovery rate method.

Datasets

The study utilized data from two groups of participants:

  • Five adult males with Fragile X Syndrome (FXS): Aged 26-48 years, with confirmed full mutation (>200 CGG repeats) of the FMR1 gene.
  • Seven age- and gender-matched healthy controls: Aged 22-43 years, with normal development.

The data collected included high-resolution structural MRI scans and dynamic PET scans acquired after injection of the [<sup>18</sup>F]FPEB radiotracer. No new benchmarks or datasets were introduced; the study focused on applying existing imaging and analysis techniques to a specific patient population.

Key Insights and Ideas

  • Reduced mGlu5 Receptor Availability in FXS: The most significant finding is the consistent observation of lower [<sup>18</sup>F]FPEB binding potential (BP<sub>ND</sub>) in males with FXS compared to healthy controls across multiple brain regions. This directly suggests a reduced availability of mGlu5 receptors in the brains of individuals with FXS.
  • Biomarker Potential of mGlu5 Receptors: The study strongly supports the idea that mGlu5 receptor availability, as measured by [<sup>18</sup>F]FPEB PET-MR, can serve as a reliable biomarker for FXS. This is crucial for advancing drug development by providing a quantifiable measure of target engagement.
  • Regional Specificity of Deficits: The observed differences in BP<sub>ND</sub> were not uniform but were particularly pronounced in brain regions known to be associated with FXS-related deficits, such as the insula, anterior cingulate cortex, parahippocampal gyrus, inferior temporal gyrus, and olfactory cortex. These regions are involved in inhibition, memory, and visuospatial processing, aligning with the known clinical presentation of FXS.
  • Robustness of the Imaging Protocol: Despite the inherent challenges of neuroimaging individuals with FXS (e.g., potential for anxiety, movement artifacts), the study highlights the robustness of their PET-MR protocol, demonstrating consistent results across subjects. This bodes well for its application in future clinical trials.

Key Results

  • A global reduction in [<sup>18</sup>F]FPEB BP<sub>ND</sub> was observed in males with FXS compared to control subjects.
  • Significant group differences (p < 0.01 after correction for multiple comparisons) in BP<sub>ND</sub> were found in the following regions:
  • Anterior cingulate gyrus: FXS (2.67±0.38) vs. Controls (3.56±0.41)
    • Insula: FXS (2.79±0.47) vs. Controls (3.67±0.36)
    • Inferior temporal gyrus: FXS (2.41±0.34) vs. Controls (3.19±0.47)
    • Parahippocampal gyrus: FXS (2.10±0.32) vs. Controls (2.65±0.32)
    • Olfactory cortex: FXS (2.27±0.30) vs. Controls (2.98±0.34)
  • A trend towards lower BP<sub>ND</sub> was also observed in the amygdala (p = 0.04), though it did not survive multiple comparison correction.

Limitations and Future Work

  • Sample Size: The study included a relatively small sample size (5 males with FXS and 7 controls). The authors acknowledge that larger studies are needed, particularly to confirm findings like the amygdala difference and to better capture the heterogeneity of FXS.
  • Age Range and Heterogeneity: While efforts were made to match age and gender, the authors suggest that future studies might benefit from narrower age ranges and more stringent methodological standards to account for the heterogeneity found in neurodevelopmental disorders.
  • Mosaicism: The study focused on individuals with the full FMR1 mutation. They note that individuals with mosaicism (varying FMRP levels) might present differently and warrant further investigation.
  • Comorbidities: While participants with FXS were screened for comorbid diagnoses and medication use, the authors acknowledge the high comorbidity of FXS with autism spectrum disorder (ASD) and suggest that future studies could explore mGluR5 differences in ASD as well.
  • Future Directions: The authors propose that this imaging protocol and the identified biomarker could be critical for optimizing drug trials, monitoring dose response, and developing targeted therapies for FXS and related neurodevelopmental conditions. They advocate for systematic interrogation of larger samples to explore the relationship between disorder severity, age, cognitive abilities, and mGluR5 availability.

Summary updated

Abstract

Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by silencing of the Fragile X Mental Retardation (FMR1) gene. The resulting loss of Fragile X Mental Retardation Protein (FMRP) leads to excessive glutamate signaling via metabotropic glutamate subtype 5 receptors (mGluR5) which has been implicated in the pathogenesis of the disorder. In the present study we used the radioligand 3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile ([<sup>18</sup>F]FPEB) in simultaneous PET-MR imaging of males with FXS and age- and gender-matched controls to assess the availability of mGlu5 receptors in relevant brain areas. Patients with FXS showed lower [<sup>18</sup>F]FPEB binding potential (p < 0.01), reflecting reduced mGluR5 availability, than the healthy controls throughout the brain, with significant group differences in insula, anterior cingulate, parahippocampal, inferior temporal and olfactory cortices, regions associated with deficits in inhibition, memory, and visuospatial processes characteristic of the disorder. The results are among the first to provide in vivo evidence of decreased availability of mGluR5 in the brain in individuals with FXS than in healthy controls. The consistent results across the subjects, despite the tremendous challenges with neuroimaging this population, highlight the robustness of the protocol and support for its use in drug occupancy studies; extending our radiotracer development and application efforts from mice to humans.
BibTeX
@inproceedings{mody2021vivo,
  author = {Maria Mody and Yoann Petibon and Paul Kyu Han and Darshini Kuruppu and Chao Ma and Daniel Yokell and Ramesh Neelamegam and Marc D. Normandin and Georges El Fakhri and Anna‐Liisa Brownell},
  title = {{In vivo imaging of mGlu5 receptor expression in humans with Fragile X Syndrome towards development of a potential biomarker}},
  booktitle = {Scientific},
  year = {2021},
  doi = {10.1038/s41598-021-94967-y},
}
Figure